|
Cardiovascular Risk
- NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at a greater risk. (See WARNINGS).
- RELAFEN is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).
Gastrointestinal Risk
- NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS).
|
| |
RELAFEN SUMMARY
RELAFEN®
(nabumetone)
Tablets
Relafen is a nonsteroidal anti-inflammatory drug (NSAID).
Relafen
is indicated for acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis.
|
|
NEWS HIGHLIGHTS
Published Studies Related to Relafen (Nabumetone)
Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients. [2009.12]
BACKGROUND:S-adenosylmethionine (SAMe) has antiinflammatory and analgesic effects and has been reported to ameliorate the pain and dysfunction of osteoarthritis (OA). The metabolism of SAMe can be affected by geographic or ethnic factors. However, its efficacy and tolerability versus NSAIDs have not been reported in an Asian population. OBJECTIVE: This study compared the efficacy and tolerability of SAMe 1200 mg/d and nabumetone 1000 mg/d in Korean patients with knee OA... CONCLUSION: This study found no significant differences in pain relief or tolerability between treatment with SAMe or nabumetone over 8 weeks in Korean patients with knee OA. Copyright 2009 Excerpta Medica Inc. All rights reserved.
The effects of aceclofenac and nabumetone in osteoarthritis. [2009.04]
INTRODUCTION: Aceclofenac, a NSAID is widely used in the treatment of pain and inflammation associated with osteoarthritis. Nabumetone, a recently developed preferential cyclo-oxygenase 2 inhibitor has also proved to be equally effective. The present study was undertaken to evaluate the 'real better' drug, amongst these with better efficacy and gastro-intestinal tolerability as well... CONCLUSIONS: The preferential inhibition of cyclo-oxygenase 2 by nabumetone was postulated to afford better clinical efficacy and gastrointestinal tolerability in osteoarthritis as compared to aceclofenac.
High-throughput LC-MS/MS assay for 6-methoxy-2-naphthylacetic acid, an active metabolite of nabumetone in human plasma and its application to bioequivalence study. [2008.11]
A simple, precise and accurate assay for the determination of 6-methoxy-2-naphthylacetic acid (6-MNA), an active metabolite of nabumetone in human plasma, was developed and validated using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The analyte (6-MNA) and propranolol (internal standard, IS) were extracted from 200 microL aliquot of human plasma via solid-phase extraction employing HLB Oasis cartridges and separated on a Discovery HS C18 (50 x 4.6 mm, 5 microm) column...
Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone. [2006.02]
BACKGROUND: Rofecoxib and nabumetone were developed to provide gastrointestinal benefits over traditional nonsteroidal antiinflammatory drugs (NSAIDs). However, there is limited comparative information relating to these 2 drugs. OBJECTIVE: The objective of this study was to compare rofecoxib and nabumetone, at their lower, recommended doses, in patients with osteoarthritis (OA)... CONCLUSIONS: At their recommended starting doses for OA, both agents were more effective than placebo. Rofecoxib at a dosage of 12.5 mg demonstrated significantly better efficacy in PGART than 1000 mg nabumetone in these patients known to be NSAID responders. Significantly more AEs occurred with rofecoxib than nabumetone. Considering these data and other recent safety information regarding cyclooxygenase-2 selective and nonselective NSAIDS, physicians must make risk/benefit assessments for each individual patient when considering the use of these agents, as recommended by the U.S. Food and Drug Administration.
Pulp-dentine complex changes and root resorption during intrusive orthodontic tooth movement in patients prescribed nabumetone. [2005.01]
Pulpitis, external root resorption, and pain may be experienced during orthodontic movement... Nabumetone was found to be useful in reducing pulpitis, external root resorption, and pain caused by intrusive orthodontic movement, without altering tooth movement in response to the application of orthodontic force.
Clinical Trials Related to Relafen (Nabumetone)
The Effect on Knee Joint Loads of Analgesic Use Compared With Exercise in Patients With Knee Osteoarthritis - An RCT [Recruiting]
The purpose of this study is to compare the effects of neuromuscular exercise and analgesic
use on knee joint load, in patients with mild to moderate knee osteoarthritis (OA).
It is expected that the two groups will receive equipotent pain relieving effect, despite
this, the investigators expect a between group difference in knee joint load, and the
exercise group will have a reduction in knee joint load.
Functional MRI (fMRI) in CGRP Induced Migraine [Not yet recruiting]
In patients known with migraine without aura a migraine headache or migraine like headache
will be induced by infusion of calcitonin gene related peptide (CGRP). The patients will then
be stimulated with noxious heat via a thermode placed at the forehead. At the same time the
Blood-oxygenation-level-dependent (BOLD) response will be measured via functional magnetic
ressonanse imaging (fMRI), to estimate the central-nervous pain response. The regions of
interest (ROI) will be thalamic region and medulla oblongata.
Then the patients will be given pain relif in form of injection of sumatriptan and the effect
of this will also be registered via measuring the BOLD response at the RIO's previously
defined. A 3-Tesla MRI scanner will be used in this trail.
This study will give us key knowledge of the trigeminal pain pathway and the central
processing i. e sensitization during a migraine attach.
Reports of Suspected Relafen (Nabumetone) Side Effects
Drug Ineffective (5),
Drug Hypersensitivity (4),
Hyperhidrosis (3),
Neck Pain (3),
Blood Testosterone Decreased (3),
Injury (3),
Back Pain (3),
Contusion (2),
Hypersensitivity (1),
Wound Haemorrhage (1), more >>
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 3 ratings/reviews, Relafen has an overall score of 6.33. The effectiveness score is 6 and the side effect score is 8.67. The scores are on ten point scale: 10 - best, 1 - worst.
| | Relafen review by 20 year old female patient | | | Rating |
| Overall rating: | |   |
| Effectiveness: | | Considerably Effective |
| Side effects: | | No Side Effects | | |
Treatment Info |
| Condition / reason: | | oral infection and swelling |
| Dosage & duration: | | 750mg taken twice a day for the period of one week |
| Other conditions: | | none |
| Other drugs taken: | | none | | |
Reported Results |
| Benefits: | | this drug helped the swelling i had in my mouth from an infected area above my wisdom tooth. it didn't help with the pain, i had to take another prescription drug to get all of the swelling and pain to a bearable level. the |
| Side effects: | | there were no side effects, i took this medicine with and without food and had no problems after. |
| Comments: | | while the drug helped with the swelling, it did take a little longer than expected, yet i did have swelling on my cheek and my gums. the drug definitely didn't seem to help with the pain, i needed something stronger to go along with the nabumetone. |
|
| | Relafen review by 53 year old female patient | | | Rating |
| Overall rating: | | |
| Effectiveness: | | Moderately Effective |
| Side effects: | | No Side Effects | | |
Treatment Info |
| Condition / reason: | | pain |
| Dosage & duration: | | 750 mg taken 2 x per day for the period of 30 days |
| Other conditions: | | none |
| Other drugs taken: | | none | | |
Reported Results |
| Benefits: | | The benefits of this treatment was slightly reduced pain due to a partial rotator cuff tear |
| Side effects: | | There were no side effects experienced with this drug |
| Comments: | | The treatment for this injury was to take the drug as prescribed in addition to physical therapy. Drug and physical therapy was prescribed for approximately six weeks. |
|
| | Relafen review by 53 year old female patient | | | Rating |
| Overall rating: | | |
| Effectiveness: | | Moderately Effective |
| Side effects: | | No Side Effects | | |
Treatment Info |
| Condition / reason: | | pain |
| Dosage & duration: | | 750 mg taken 2 x per day for the period of 30 days |
| Other conditions: | | none |
| Other drugs taken: | | none | | |
Reported Results |
| Benefits: | | The benefits of this treatment was slightly reduced pain due to a partial rotator cuff tear |
| Side effects: | | There were no side effects experienced with this drug |
| Comments: | | The treatment for this injury was to take the drug as prescribed in addition to physical therapy. Drug and physical therapy was prescribed for approximately six weeks. |
|
|
|
Page last updated: 2010-10-05
|
